Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Govt Deregulation Panel Calls for Revisiting 14-Day Prescription Limit
The government’s Regulatory Reform Council submitted a recommendation on June 16 calling for revising a 14-day prescription limit imposed on newly approved drugs during their first year on the market. Based on this recommendation, handed to Prime Minister Shinzo Abe,…
To read the full story
Related Article
- Deregulation Panel Calls for Revisiting Plasma Export Restrictions, Wants Conclusion by FY2018
May 20, 2016
- 14-Day Prescription Limit to Be Discussed toward Next Reform: MHLW Official
April 4, 2016
- Govt OKs Economic Growth Strategy, Regulatory Reform Plan
July 1, 2015
- MHLW to Launch Switch OTC Panel as Early as Summer
June 3, 2015
- Govt Panel to Prod Chuikyo to Revisit 14-Day Prescription Limit
April 17, 2015
- JPA Vice President Disagrees with Exclusion of OTC-Like Drugs from Insurance Coverage
April 13, 2015
- Set Ceiling for Health Coverage of OTC-Like Drugs: Govt Panel
April 9, 2015
- 1st Generation Poultices “Just One Example” for Proposal to Scrap Health Coverage for OTC-Like Drugs: Shirakawa
March 26, 2015
- Govt Panel Members Push Deregulation of Bungyo Rules
March 16, 2015
REGULATORY
- Nakai Tapped as MHLW’s Top Pharmacy Officer; Ohara to Steer Drug Pricing Reform
August 7, 2026
- Sarclisa SC, Joenja, Kineret, and 7 More Drugs Bound for NHI Listing
August 6, 2026
- Tepezza Price Cut Set at 5.5% under Japan’s CEA Scheme
August 6, 2026
- Dupixent Faces Fourth Re-Pricing under Japan’s SPA-SSS
August 6, 2026
- Chuikyo Clears NHI Listing for Oncolys’ Telomelysin
August 6, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…